0 XP   0   0   0

Celyad SA
Buy, Hold or Sell?

Should you buy, hold or sell Celyad?

I guess you are interested in Celyad SA. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Celyad

Let's start. I'm going to help you getting a better view of Celyad SA. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Celyad SA even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Celyad SA is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Celyad SA. The closing price on 2023-02-03 was €1.22 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Celyad SA Daily Candlestick Chart
Celyad SA Daily Candlestick Chart
Summary









1. Valuation of Celyad




Current price per share

€1.22

2. Growth of Celyad




Is Celyad growing?

Current yearPrevious yearGrowGrow %
How rich?$47.1m$33.4m$13.6m29.0%

How much money is Celyad making?

Current yearPrevious yearGrowGrow %
Making money-$28.6m-$18.5m-$10m-35.1%
Net Profit Margin0.0%-344,080.0%--

How much money comes from the company's main activities?

3. Financial Health of Celyad




Comparing to competitors in the Biotechnology industry




  Industry Rankings (Biotechnology)  


Richest
#693 / 1232

Most Revenue
#1202 / 1232

Most Profit
#899 / 1232

Most Efficient
#570 / 1232


Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Celyad SA.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Celyad earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Celyad to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that €0.00 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Celyad SA:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-344,080.0%+344,080.0%
TTM-5Y-164,814.9%+164,814.9%
5Y-164,814.9%10Y-181,007.4%+16,192.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--223.6%+223.6%
TTM--281.7%+281.7%
YOY-344,080.0%-344.8%-343,735.2%
5Y-164,814.9%-450.1%-164,364.8%
10Y-181,007.4%-541.0%-180,466.4%
1.1.2. Return on Assets

Shows how efficient Celyad is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Celyad to the Biotechnology industry mean.
  • -33.2% Return on Assets means that Celyad generated €-0.33 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Celyad SA:

  • The MRQ is -33.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -33.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-33.2%TTM-33.2%0.0%
TTM-33.2%YOY-26.0%-7.1%
TTM-33.2%5Y-40.7%+7.5%
5Y-40.7%10Y-33.0%-7.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-33.2%-9.9%-23.3%
TTM-33.2%-8.9%-24.3%
YOY-26.0%-9.3%-16.7%
5Y-40.7%-11.7%-29.0%
10Y-33.0%-12.7%-20.3%
1.1.3. Return on Equity

Shows how efficient Celyad is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Celyad to the Biotechnology industry mean.
  • -60.8% Return on Equity means Celyad generated €-0.61 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Celyad SA:

  • The MRQ is -60.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -60.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-60.8%TTM-60.8%0.0%
TTM-60.8%YOY-55.5%-5.2%
TTM-60.8%5Y-73.0%+12.2%
5Y-73.0%10Y-55.2%-17.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-60.8%-12.0%-48.8%
TTM-60.8%-11.5%-49.3%
YOY-55.5%-10.8%-44.7%
5Y-73.0%-14.2%-58.8%
10Y-55.2%-15.2%-40.0%

1.2. Operating Efficiency of Celyad SA.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Celyad is operating .

  • Measures how much profit Celyad makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Celyad to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Celyad SA:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-338,140.0%+338,140.0%
TTM-5Y-162,509.2%+162,509.2%
5Y-162,509.2%10Y-179,519.6%+17,010.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.3%+207.3%
TTM--271.0%+271.0%
YOY-338,140.0%-325.9%-337,814.1%
5Y-162,509.2%-454.0%-162,055.2%
10Y-179,519.6%-537.1%-178,982.5%
1.2.2. Operating Ratio

Measures how efficient Celyad is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are €0.00 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Celyad SA:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY5,248.800-5,248.800
TTM-5Y2,032.989-2,032.989
5Y2,032.98910Y2,025.892+7.097
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.871-2.871
TTM-3.504-3.504
YOY5,248.8003.604+5,245.196
5Y2,032.9895.132+2,027.857
10Y2,025.8926.371+2,019.521

1.3. Liquidity of Celyad SA.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Celyad is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.48 means the company has €2.48 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Celyad SA:

  • The MRQ is 2.480. The company is able to pay all its short-term debts. +1
  • The TTM is 2.480. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.480TTM2.4800.000
TTM2.480YOY1.665+0.815
TTM2.4805Y3.535-1.055
5Y3.53510Y4.769-1.233
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4805.117-2.637
TTM2.4805.755-3.275
YOY1.6655.854-4.189
5Y3.5356.511-2.976
10Y4.7696.222-1.453
1.3.2. Quick Ratio

Measures if Celyad is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Celyad to the Biotechnology industry mean.
  • A Quick Ratio of 2.34 means the company can pay off €2.34 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Celyad SA:

  • The MRQ is 2.340. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.340. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.340TTM2.3400.000
TTM2.340YOY1.533+0.807
TTM2.3405Y3.890-1.550
5Y3.89010Y5.405-1.515
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3404.284-1.944
TTM2.3404.664-2.324
YOY1.5334.787-3.254
5Y3.8905.218-1.328
10Y5.4055.182+0.223

1.4. Solvency of Celyad SA.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Celyad assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Celyad to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.45 means that Celyad assets are financed with 45.4% credit (debt) and the remaining percentage (100% - 45.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Celyad SA:

  • The MRQ is 0.454. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.454. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.454TTM0.4540.000
TTM0.454YOY0.531-0.077
TTM0.4545Y0.455-0.001
5Y0.45510Y0.489-0.034
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4540.278+0.176
TTM0.4540.277+0.177
YOY0.5310.306+0.225
5Y0.4550.367+0.088
10Y0.4890.403+0.086
1.4.2. Debt to Equity Ratio

Measures if Celyad is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Celyad to the Biotechnology industry mean.
  • A Debt to Equity ratio of 83.2% means that company has €0.83 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Celyad SA:

  • The MRQ is 0.832. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.832. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.832TTM0.8320.000
TTM0.832YOY1.132-0.300
TTM0.8325Y0.853-0.021
5Y0.85310Y0.679+0.174
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8320.315+0.517
TTM0.8320.317+0.515
YOY1.1320.319+0.813
5Y0.8530.403+0.450
10Y0.6790.462+0.217

2. Market Valuation of Celyad SA

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Celyad generates.

  • Above 15 is considered overpriced but always compare Celyad to the Biotechnology industry mean.
  • A PE ratio of -4.17 means the investor is paying €-4.17 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Celyad SA:

  • The EOD is -1.448. Company is losing money. -2
  • The MRQ is -4.172. Company is losing money. -2
  • The TTM is -4.172. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-1.448MRQ-4.172+2.724
MRQ-4.172TTM-4.1720.000
TTM-4.172YOY-8.694+4.522
TTM-4.1725Y-8.880+4.708
5Y-8.88010Y-18.540+9.660
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.448-8.986+7.538
MRQ-4.172-9.792+5.620
TTM-4.172-16.243+12.071
YOY-8.694-20.876+12.182
5Y-8.880-16.665+7.785
10Y-18.540-14.732-3.808
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Celyad.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Celyad SA:

  • The MRQ is -4.669. Very Bad. -2
  • The TTM is -4.669. Very Bad. -2
Trends
Current periodCompared to+/- 
MRQ-4.669TTM-4.6690.000
TTM-4.669YOY-6.214+1.545
TTM-4.6695Y2.214-6.883
5Y2.21410Y-23.519+25.733
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.669-0.032-4.637
TTM-4.6690.004-4.673
YOY-6.2140.016-6.230
5Y2.2140.006+2.208
10Y-23.5190.003-23.522

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Celyad is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.53 means the investor is paying €2.53 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Celyad SA:

  • The EOD is 0.880. Very good. +2
  • The MRQ is 2.535. Good. +1
  • The TTM is 2.535. Good. +1
Trends
Current periodCompared to+/- 
EOD0.880MRQ2.535-1.655
MRQ2.535TTM2.5350.000
TTM2.535YOY4.826-2.291
TTM2.5355Y7.072-4.537
5Y7.07210Y11.246-4.175
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.8801.835-0.955
MRQ2.5352.006+0.529
TTM2.5352.774-0.239
YOY4.8263.453+1.373
5Y7.0722.713+4.359
10Y11.2462.402+8.844
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Celyad SA compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0150.0150%-0.647+4430%-0.527+3626%0.135-89%
Book Value Growth--1.4081.4080%0.679+107%0.920+53%2.449-42%
Book Value Per Share--1.3871.3870%1.372+1%1.868-26%2.017-31%
Book Value Per Share Growth--1.0111.0110%0.679+49%0.841+20%2.409-58%
Current Ratio--2.4802.4800%1.665+49%3.535-30%4.769-48%
Debt To Asset Ratio--0.4540.4540%0.531-14%0.4550%0.489-7%
Debt To Equity Ratio--0.8320.8320%1.132-27%0.853-2%0.679+23%
Dividend Per Share----0%-0%-0%-0%
Eps---0.842-0.8420%-0.761-10%-1.405+67%-1.082+28%
Eps Growth--0.8940.8940%1.399-36%0.8950%0.225+297%
Free Cash Flow Per Share---0.859-0.8590%-1.239+44%-1.332+55%-1.077+25%
Free Cash Flow Per Share Growth--1.3061.3060%1.029+27%0.998+31%0.848+54%
Free Cash Flow To Equity Per Share--0.3970.3970%-1.000+352%-0.478+220%0.155+156%
Free Cash Flow To Equity Per Share Growth--2.3972.3970%-0.141+106%0.795+201%22.956-90%
Gross Profit Margin--1.0001.0000%1.0000%1.006-1%1.013-1%
Intrinsic Value_10Y_max---13.680--------
Intrinsic Value_10Y_min---11.559--------
Intrinsic Value_1Y_max---0.972--------
Intrinsic Value_1Y_min---0.944--------
Intrinsic Value_3Y_max---3.224--------
Intrinsic Value_3Y_min---3.039--------
Intrinsic Value_5Y_max---5.842--------
Intrinsic Value_5Y_min---5.340--------
Net Profit Margin----0%-3440.8000%-1648.1490%-1810.0740%
Operating Margin----0%-3381.4000%-1625.0920%-1795.1960%
Operating Ratio----0%5248.800-100%2032.989-100%2025.892-100%
Pb Ratio0.880-188%2.5352.5350%4.826-47%7.072-64%11.246-77%
Pe Ratio-1.448+65%-4.172-4.1720%-8.694+108%-8.880+113%-18.540+344%
Peg Ratio---4.669-4.6690%-6.214+33%2.214-311%-23.519+404%
Price Per Share1.220-188%3.5153.5150%6.620-47%14.207-75%19.670-82%
Price To Total Gains Ratio81.607-188%235.122235.1220%-10.227+104%46.283+408%37.193+532%
Profit Growth--0.4590.4590%1.399-67%0.808-43%0.416+10%
Quick Ratio--2.3402.3400%1.533+53%3.890-40%5.405-57%
Return On Assets---0.332-0.3320%-0.260-21%-0.407+23%-0.330-1%
Return On Equity---0.608-0.6080%-0.555-9%-0.730+20%-0.552-9%
Revenue Growth----0%0.833-100%0.426-100%316.128-100%
Total Gains Per Share--0.0150.0150%-0.647+4430%-0.527+3626%0.135-89%
Total Gains Per Share Growth--2.0232.0230%0.533+279%0.680+198%2.454-18%
Usd Book Value--47108300.50047108300.5000%33458023.000+41%48226878.400-2%50520986.282-7%
Usd Book Value Change Per Share--0.0160.0160%-0.699+4430%-0.569+3626%0.146-89%
Usd Book Value Per Share--1.4971.4970%1.481+1%2.017-26%2.177-31%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.909-0.9090%-0.822-10%-1.516+67%-1.168+28%
Usd Free Cash Flow---29185362.000-29185362.0000%-30208728.000+4%-34146096.300+17%-27094331.638-7%
Usd Free Cash Flow Per Share---0.927-0.9270%-1.337+44%-1.438+55%-1.163+25%
Usd Free Cash Flow To Equity Per Share--0.4280.4280%-1.079+352%-0.516+220%0.167+156%
Usd Price Per Share1.317-188%3.7943.7940%7.146-47%15.336-75%21.233-82%
Usd Profit---28619704.000-28619704.0000%-18571718.000-35%-35876103.000+25%-26970418.587-6%
Usd Revenue----0%5397.500-100%1439189.400-100%1661566.400-100%
Usd Total Gains Per Share--0.0160.0160%-0.699+4430%-0.569+3626%0.146-89%
 EOD+2 -3MRQTTM+0 -0YOY+25 -125Y+26 -1210Y+14 -24

3.2. Fundamental Score

Let's check the fundamental score of Celyad SA based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.448
Price to Book Ratio (EOD)Between0-10.880
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.340
Current Ratio (MRQ)Greater than12.480
Debt to Asset Ratio (MRQ)Less than10.454
Debt to Equity Ratio (MRQ)Less than10.832
Return on Equity (MRQ)Greater than0.15-0.608
Return on Assets (MRQ)Greater than0.05-0.332
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Celyad SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.099
Ma 20Greater thanMa 501.306
Ma 50Greater thanMa 1001.017
Ma 100Greater thanMa 2001.129
OpenGreater thanClose1.252
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2021-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets79,943
Total Liabilities36,304
Total Stockholder Equity43,639
 As reported
Total Liabilities 36,304
Total Stockholder Equity+ 43,639
Total Assets = 79,943

Assets

Total Assets79,943
Total Current Assets34,292
Long-term Assets34,292
Total Current Assets
Cash And Cash Equivalents 30,018
Net Receivables 2,340
Other Current Assets 1,934
Total Current Assets  (as reported)34,292
Total Current Assets  (calculated)34,292
+/-0
Long-term Assets
Property Plant Equipment 3,248
Goodwill 883
Intangible Assets 35,285
Long-term Assets Other 6,235
Long-term Assets  (as reported)45,651
Long-term Assets  (calculated)45,651
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities13,827
Long-term Liabilities22,477
Total Stockholder Equity43,639
Total Current Liabilities
Short-term Debt 902
Accounts payable 6,611
Other Current Liabilities 4,856
Total Current Liabilities  (as reported)13,827
Total Current Liabilities  (calculated)12,369
+/- 1,458
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt1,730
Other Liabilities 20,747
Long-term Liabilities  (as reported)22,477
Long-term Liabilities  (calculated)22,477
+/-0
Total Stockholder Equity
Common Stock78,585
Retained Earnings -308,997
Accumulated Other Comprehensive Income 267,734
Other Stockholders Equity 6,317
Total Stockholder Equity (as reported)43,639
Total Stockholder Equity (calculated)43,639
+/-0
Other
Capital Stock78,585
Cash and Short Term Investments 30,018
Common Stock Shares Outstanding 31,469
Current Deferred Revenue1,458
Liabilities and Stockholders Equity 79,943
Net Debt -27,386
Net Invested Capital 43,639
Net Tangible Assets 7,945
Net Working Capital 20,465
Short Long Term Debt Total 2,632



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-31
> Total Assets 
17,495
6,877
13,746
32,386
43,976
159,524
138,807
77,626
94,299
89,836
66,084
79,943
79,94366,08489,83694,29977,626138,807159,52443,97632,38613,7466,87717,495
   > Total Current Assets 
0
3,469
2,192
22,602
32,935
109,419
85,367
36,394
51,692
42,836
19,705
34,292
34,29219,70542,83651,69236,39485,367109,41932,93522,6022,1923,4690
       Cash And Cash Equivalents 
3,827
1,751
1,645
19,058
27,633
100,175
48,357
23,253
40,542
39,338
17,234
30,018
30,01817,23439,33840,54223,25348,357100,17527,63319,0581,6451,7513,827
       Short-term Investments 
0
0
0
3,000
2,671
7,338
34,230
10,653
9,197
0
0
0
0009,19710,65334,2307,3382,6713,000000
       Net Receivables 
1,988
1,667
443
421
1,717
1,075
1,503
1,592
1,269
2,702
907
2,340
2,3409072,7021,2691,5921,5031,0751,7174214431,6671,988
   > Long-term Assets 
0
3,408
11,554
9,783
11,041
50,105
53,440
41,232
42,607
47,000
46,379
45,651
45,65146,37947,00042,60741,23253,44050,10511,0419,78311,5543,4080
       Property Plant Equipment 
592
355
383
243
598
1,136
3,563
3,290
3,014
5,061
4,119
3,248
3,2484,1195,0613,0143,2903,5631,136598243383355592
       Goodwill 
0
0
0
0
0
1,003
1,040
914
883
883
883
883
8838838838839141,0401,00300000
       Long Term Investments 
0
0
0
0
68
0
0
0
0
0
0
0
0000000680000
       Intangible Assets 
10,205
9,625
9,087
9,400
10,266
47,786
48,526
35,594
35,281
35,316
35,288
35,285
35,28535,28835,31635,28135,59448,52647,78610,2669,4009,0879,62510,205
       Long-term Assets Other 
0
183
0
140
109
180
311
1,434
3,429
5,740
6,089
6,235
6,2356,0895,7403,4291,43431118010914001830
> Total Liabilities 
8,805
6,037
15,058
15,488
17,292
48,052
47,921
30,091
38,710
44,217
35,090
36,304
36,30435,09044,21738,71030,09147,92148,05217,29215,48815,0586,0378,805
   > Total Current Liabilities 
2,242
5,921
2,731
3,389
6,053
11,490
11,275
7,945
9,647
11,922
11,834
13,827
13,82711,83411,9229,6477,94511,27511,4906,0533,3892,7315,9212,242
       Short-term Debt 
0
0
248
79
134
248
561
636
765
1,359
1,113
902
9021,1131,3597656365612481347924800
       Short Long Term Debt 
0
0
0
106
413
976
207
209
281
192
37
0
037192281209207976413106000
       Accounts payable 
1,287
1,086
1,770
2,169
4,042
8,576
8,098
4,800
5,916
6,969
4,736
6,611
6,6114,7366,9695,9164,8008,0988,5764,0422,1691,7701,0861,287
       Other Current Liabilities 
664
4,835
712
712
1,100
1,768
1,508
2,283
1,339
3,248
3,776
4,856
4,8563,7763,2481,3392,2831,5081,7681,1007127124,835664
   > Long-term Liabilities 
0
116
12,328
12,099
11,239
36,562
36,646
22,146
29,063
32,295
23,256
22,477
22,47723,25632,29529,06322,14636,64636,56211,23912,09912,3281160
       Long term Debt Total 
0
0
0
0
0
427
917
808
881
3,004
0
0
003,00488180891742700000
       Capital Lease Obligations Min Short Term Debt
0
0
-248
-79
-134
-248
174
273
371
2,775
2,488
1,730
1,7302,4882,775371273174-248-134-79-24800
       Long-term Liabilities Other 
0
0
0
0
0
0
28,195
19,590
25,187
0
371
164
164371025,18719,59028,195000000
       Deferred Long Term Liability 
0
0
0
925
911
872
805
739
673
607
541
474
474541607673739805872911925000
> Total Stockholder Equity
8,690
840
-1,312
16,898
26,684
111,473
90,884
47,535
55,591
45,619
30,994
43,639
43,63930,99445,61955,59147,53590,884111,47326,68416,898-1,3128408,690
   Retained Earnings -308,997-91,826-74,424-217,778-180,421-124,026-100,313-71,215-36,388-11,287-9,1340
   Accumulated Other Comprehensive Income 
0
0
0
-1,872
19,982
21,205
24,329
23,322
25,667
28,181
30,958
267,734
267,73430,95828,18125,66723,32224,32921,20519,982-1,872000
   Capital Surplus 
0
0
0
0
0
158,010
158,010
170,297
206,149
43,349
0
0
0043,349206,149170,297158,010158,01000000
   Treasury Stock000000000000



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-26,909
Operating Income-26,391-26,909
 
Operating Expense (+$)
Research Development20,773
Selling General Administrative9,665
Selling And Marketing Expenses-
Operating Expense26,90930,438
 
Net Interest Income (+$)
Interest Income27
Interest Expense-255
Net Interest Income-116-228
 
Pretax Income (+$)
Operating Income-26,391
Net Interest Income-116
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-26,502-26,280
EBIT - interestExpense = -26,502
-26,502
-26,257
Interest Expense255
Earnings Before Interest and Taxes (ebit)-26,247-26,247
Earnings Before Interest and Taxes (ebitda)-24,727
 
After tax Income (+$)
Income Before Tax-26,502
Tax Provision-10
Net Income From Continuing Ops-26,512-26,512
Net Income-26,512
Net Income Applicable To Common Shares-26,512
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses26,909
Total Other Income/Expenses Net-111116
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
0QNM.LSE
3 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 0QNM.LSE.

0QNM.LSE Daily Candlestick Chart
0H59.LSE
4 minutes ago

I found you a Golden Cross on the daily chart of 0H59.LSE.

0H59.LSE Daily Candlestick Chart
CNT.F
10 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CNT.F.

CNT.F Daily Candlestick Chart
CNB.F
10 minutes ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of CNB.F.

CNB.F Daily Candlestick Chart
CMID.F
11 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of CMID.F.

CMID.F Daily Candlestick Chart
CIE1.F
13 minutes ago

I found you a Golden Cross on the daily chart of CIE1.F.

CIE1.F Daily Candlestick Chart
CF3.F
18 minutes ago

I found you a Three White Soldiers Candle Pattern on the daily chart of CF3.F.

CF3.F Daily Candlestick Chart
0NQE.LSE
20 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 0NQE.LSE.

0NQE.LSE Daily Candlestick Chart
C6R.F
26 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of C6R.F.

C6R.F Daily Candlestick Chart
C0B.F
26 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of C0B.F.

C0B.F Daily Candlestick Chart
V3AL.XETRA
27 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of V3AL.XETRA.

V3AL.XETRA Daily Candlestick Chart
B46.F
30 minutes ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of B46.F.

B46.F Daily Candlestick Chart
AP4N.F
31 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of AP4N.F.

AP4N.F Daily Candlestick Chart
9RP.F
33 minutes ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of 9RP.F.

9RP.F Daily Candlestick Chart
9R8.F
33 minutes ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of 9R8.F.

9R8.F Daily Candlestick Chart
99B.F
35 minutes ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of 99B.F.

99B.F Daily Candlestick Chart
8ZM.F
36 minutes ago

I found you a RSI Bullish Reversal Divergence on the daily chart of 8ZM.F.

8ZM.F Daily Candlestick Chart
8ZF.F
36 minutes ago

I found you a Death Cross on the daily chart of 8ZF.F.

8ZF.F Daily Candlestick Chart
8V6.F
37 minutes ago

I found you a RSI Bearish Reversal Divergence on the daily chart of 8V6.F.

8V6.F Daily Candlestick Chart
8SA.F
37 minutes ago

I found you a RSI Bullish Hidden Divergence on the daily chart of 8SA.F.

8SA.F Daily Candlestick Chart
86C.F
38 minutes ago

I found you a Golden Cross on the daily chart of 86C.F.

86C.F Daily Candlestick Chart
83H.F
39 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of 83H.F.

83H.F Daily Candlestick Chart
7W71.F
39 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 7W71.F.

7W71.F Daily Candlestick Chart
7TV.F
39 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of 7TV.F.

7TV.F Daily Candlestick Chart
7IZ.F
40 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of 7IZ.F.

7IZ.F Daily Candlestick Chart